Novel melanoma antigen peptide and uses thereof

The invention relates to peptides derived from the MELOE antigen for therapeutic vaccination against cancer. A phase I clinical trial for ex-vivo therapy of melonama is ongoing.

Keywords: MELOE, antigen, cancer, melanoma, TIL, vaccination
Patent Application number: PCT/FR2012/051143
Inventors:
Nathalie LABARRIEREAnne ROGELFrançois LANGMathilde BOBINET

You might also be interested in

Contact

Inserm Transfert

Research tool licensing team

researchtools@inserm-transfert.fr